ISSN: 2278-0238

Internationale Zeitschrift für Forschung und Entwicklung in Pharmazie und Biowissenschaften

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

The Case Study of Nephrotic Syndrome Control of Hyperlipidemia with Nephrotic Syndrome Using Hmg Coa Inhibitors: A Nested Case Study

Deepak Kumar Punna, Naveen Kumar Bathula

Introduction: The essential of cholesterol control is the use of HMG-COA inhibitors, but very few researches to date have directed on using what subjects accompanying nephrotic disease put oneself in the place of another cardiovascular occurrence.

Objective: To judge whether either HMG-COA inhibitors situation impacts the consequences of cardiovascular occurrence accompanying nephrotic condition.

Design: A sole center backward-looking reside case-control study resolved dossier from Vijaya Krishna multispecialty hospital, SVR kidney center, Area Hospital Suryapet.

Patients: Patient investigated accompanying nephrotic disease from January 1st, 2022 to December 31st, 2022

Measurement and main results: The research group contained 350 NS victims in total. At the judgment of the practical ending, 65 of these inmates were raised to have heart failure (CVD), and 2 CVD-free controls were contained by 1:2 corresponding accompanying common, age, and index period. To competition the criterion traits of the cases and controls (1:1), the weakness score corresponding was acted. The square test was run utilizing the patient's habit as an uncovering determinant, and a twofold logistic reversion study was approved to examine the friendship between the distance of HMG-COA inhibitors situation cure and cardiovascular occurrences. Additionally, subgroup studies for suitable determinants were completed activity. The square test told that HMG-COA inhibitors situation drug was essentially connected to a decrease in inmates' risk of CVD. NS abated as the distance of HMG-COA inhibitors situation raised (OR = 0.82 [95% CI 0.73– 0.89], p < 0.001).

Conclusions: For NS patients with dyslipidemia, HMG-COA inhibitor therapy may be used to decrease CVD risk, and extended treatment was associated with more significant risk reduction.